The IGF-1R/IR Tyrosine Kinase Inhibitor PQIP Exhibits Enhanced Anti-Tumor Effects in Combination with Chemotherapy Against Colorectal Cancer Models

摘要

PurposeThere is growing evidence implicating the importance of the insulin-like growth factor (IGF) pathway in colorectal cancer (CRC) based upon the results of population studies, and preclinical experiments. However, the combination of an IGF-1 receptor (IGF-1R) inhibitor with standard CRC chemotherapies has not yet been evaluated. In this study, we investigated the interaction between the dual IGF-1R/IR tyrosine kinase inhibitor (TKI), PQIP, and standard chemotherapies in CRC cell line models.